Study wrapper · #71
Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.
Editor's note
This is the most clinically significant study in the batch — and it needs careful reading. Alongside mouse ischemia-reperfusion work, it includes a randomised, double-blind, placebo-controlled trial of recombinant human thymosin beta-4 in 96 STEMI (heart attack) patients after stent treatment. The headline is mixed, not positive: infarct area was significantly smaller in the subgroup dosed early (within 8 hours of PCI, n=43) at 90 days, but across the full 96-patient cohort there was no significant difference versus placebo. That distinction matters — a subgroup signal is hypothesis-generating, not a demonstration of benefit, and the authors themselves call for further rigorous trials. The mechanistic work (ErbB2/Raf1 signalling, reduced apoptosis) is coherent and the human trial is a genuine step above the rest of this literature, but the agent studied is recombinant human Tβ4, not the synthetic TB-500 fragment. Weigh this as promising but unproven early human evidence. Note the overall primary endpoint was not met.
Plain-language abstract
This study combined animal work with a small human trial. In mice with simulated heart attacks, a 7-day course of recombinant human thymosin beta-4 (rhTB4) was associated with better heart function, less scarring and smaller damaged areas, apparently by activating a cell-survival signalling pathway (ErbB2) that reduced heart-cell death. The human part was a randomised, double-blind, placebo-controlled trial in 96 people who had a major heart attack (STEMI) and were treated with a stent. Patients who received rhTB4 early — within 8 hours of the procedure (43 people) — had significantly smaller areas of heart damage at 90 days than placebo. However, across all 96 patients combined, the difference in damage was not statistically significant. The authors say larger, rigorous trials are needed. So the results are encouraging in an early-dose subgroup but do not yet establish benefit. Note this used a recombinant human peptide, not the injectable TB-500 fragment. The abstract does not detail specific side effects.